How India Exports Benzylpenicillin to the World

In the United States, benzylpenicillin is subject to stringent regulatory oversight by the Food and Drug Administration (FDA). The FDA's Orange Book lists approved Abbreviated New Drug Applications (ANDAs) for benzylpenicillin, indicating the availability of generic versions. As of March 2026, there are multiple approved ANDAs for benzylpenicillin, reflecting a competitive market landscape. Notably, in October 2024, the FDA issued Import Alert 66-72, which pertains to the detention without physical examination of misbranded drugs and marketed new drugs without approved applications. While this alert does not specifically mention benzylpenicillin, it underscores the importance of compliance with FDA regulations for all pharmaceutical imports. Given that 41 Indian exporters are actively involved in exporting benzylpenicillin, adherence to FDA guidelines is crucial to ensure market access and avoid regulatory hurdles.

In the European Union (EU) and the United Kingdom (UK), benzylpenicillin is regulated by the European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA), respectively. Marketing authorization for benzylpenicillin requires compliance with EU Good Manufacturing Practice (GMP) standards, which ensure the quality and safety of pharmaceutical products. Manufacturers must obtain a Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines (EDQM) to demonstrate compliance with the European Pharmacopoeia monograph for benzylpenicillin. Additionally, the EMA's Committee for Medicinal Products for Veterinary Use (CVMP) issued an opinion in January 2003 recommending the suspension of marketing authorizations for veterinary medicinal products containing benzathine benzylpenicillin intended for administration to food-producing species, highlighting the stringent regulatory environment in the EU.

Benzylpenicillin is included in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its importance in global health. The International Pharmacopoeia, published by WHO, provides specifications and test methods for benzylpenicillin to ensure its quality and efficacy. These standards serve as a reference for national pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), facilitating harmonization of quality specifications worldwide.

In India, benzylpenicillin is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of essential medicines, including benzylpenicillin, to ensure affordability. Manufacturers intending to export benzylpenicillin must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT), ensuring compliance with export regulations and quality standards.

The primary patents for benzylpenicillin have long expired, leading to a competitive market with multiple generic manufacturers. This generic competition has resulted in reduced prices and increased accessibility, benefiting healthcare systems globally.

In April 2025, the WHO Prequalification Team issued guidance on the design of bioequivalence studies for benzathine benzylpenicillin, aiming to standardize study protocols and ensure the quality of generic formulations. In October 2024, the FDA issued Import Alert 66-72, focusing on the detention without physical examination of misbranded drugs and marketed new drugs without approved applications, emphasizing the need for compliance with regulatory standards. In July 2025, the WHO Prequalification Team released updated notes on the design of bioequivalence studies for benzathine benzylpenicillin, providing further clarity on study requirements. In September 2024, the FDA requested Azurity Pharmaceuticals Inc. to stop distributing unapproved drugs marketed as "Unit-of-Use Prescription Compounding Kits," highlighting the agency's commitment to ensuring drug safety and efficacy. In October 2024, the FDA issued Import Alert 57-15, concerning the detention without physical examination of unlicensed allergenic products, reflecting ongoing regulatory vigilance.

The production of Benzylpenicillin in India heavily relies on Key Starting Materials (KSMs) and Active Pharmaceutical Ingredients (APIs) sourced from China. Historically, India has imported approximately 70% of its bulk drug requirements from China, creating significant supply chain vulnerabilities. This dependency exposes the supply chain to risks associated with geopolitical tensions, trade restrictions, and quality control issues.

In response to these challenges, the Indian government launched the Production Linked Incentive (PLI) Scheme for Bulk Drugs in 2020, aiming to reduce import dependence by promoting domestic manufacturing of critical KSMs, DIs, and APIs. As of August 2025, 32 pharmaceutical firms have been selected for greenfield projects, with 48 projects approved across 33 APIs/DIs/KSMs. This initiative is expected to bolster domestic production capacity and mitigate risks associated with external dependencies.

The export market for Benzylpenicillin is highly concentrated, with the top five exporters accounting for 75.6% of total exports. MEDREICH LIMITED alone contributes 50.4% of the export value, amounting to $1.9 million USD. Such concentration poses significant risks, as disruptions affecting these key suppliers could severely impact the global supply chain.

The PLI Scheme for Pharmaceuticals, initiated in 2020, aims to diversify the supplier base by encouraging new entrants and expanding existing capacities. The scheme has a financial outlay of ₹6,940 crore and covers 41 products, including critical KSMs, DIs, and APIs. By incentivizing domestic production, the scheme seeks to reduce reliance on a limited number of suppliers and enhance supply chain resilience.

Global shipping routes, including the Red Sea and the Strait of Hormuz, are susceptible to geopolitical tensions and conflicts, which can disrupt the transportation of pharmaceutical products. Additionally, ongoing US-China trade tensions have led to tariffs and export restrictions, further complicating the supply chain for APIs and KSMs.

Regulatory bodies such as the FDA and EMA have issued shortage alerts for various antibiotics, including penicillins, highlighting the fragility of the supply chain. For instance, in 2014, quality issues at a Chinese API manufacturer led to the withdrawal of benzylpenicillin products from the EU market, causing significant supply disruptions.

• Diversify Supplier Base: Encourage the development of alternative suppliers for Benzylpenicillin and its raw materials to reduce reliance on a limited number of exporters.

• Enhance Domestic Production: Support initiatives under the PLI Scheme to boost domestic manufacturing of critical APIs and KSMs, thereby decreasing dependence on imports.

• Strengthen Quality Control: Implement stringent quality assurance protocols to ensure compliance with international standards, minimizing the risk of regulatory actions and supply disruptions.

• Monitor Geopolitical Developments: Establish a dedicated task force to assess and respond to geopolitical events that may impact supply chains, ensuring timely mitigation strategies.

• Develop Contingency Plans: Create comprehensive contingency plans, including alternative shipping routes and inventory management strategies, to address potential disruptions in the supply chain.

RISK_LEVEL: MEDIUM